Immune Design (IMDZ) Tops Q1 EPS by 8c

Immune Design (NASDAQ: IMDZ) reported Q1 EPS of ($0.56), $0.08 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.3 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• PSQ Holdings announces 1-for-15 reverse stock split effective July 13
• SanDisk surges as Meta memo confirms multi-year flash storage deal